
Sign up to save your podcasts
Or


Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
By Audible4.6
1255912,559 ratings
Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback?
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

30,609 Listeners

10,415 Listeners

30,233 Listeners

772 Listeners

465 Listeners

19,197 Listeners

2,161 Listeners

19,133 Listeners

2,146 Listeners

123 Listeners

3,047 Listeners

22,977 Listeners

11,059 Listeners

904 Listeners

1,464 Listeners

7,792 Listeners

255 Listeners

2,591 Listeners

253 Listeners

2,160 Listeners

7,399 Listeners

852 Listeners

1,529 Listeners

238 Listeners

628 Listeners

66 Listeners

538 Listeners

873 Listeners

209 Listeners